

Title: Safety of meningococcal group B vaccination in hospitalised premature infants

Authors:

Alison Kent¹, Kazim Beebeejaun², Serena Braccio^{1,2}, Seilesh Kadambari³, Paul Clarke^{4,5}, Paul T Heath^{1,6}, Shamez N Ladhani^{1,2}; and the National Neonatal Audit Network

Author affiliations:

¹ Paediatric Infectious Diseases Research Group & Vaccine Institute, Institute of Infection & Immunity, St. Georges, University of London

² Public Health England, Department of Immunisation, Hepatitis and Blood Safety, Colindale, London

³ Croydon University Hospital, Croydon, UK

⁴ Norfolk & Norwich University Hospitals NHS Trust, Norwich, UK

⁵ Norwich Medical School, University of East Anglia, Norwich, UK

⁶ St George's University Hospitals NHS Trust, London, UK

National Neonatal Audit Network

- Alder Hey Children's NHS Foundation Trust: Andrew Riordan (Andrew.Riordan@alderhey.nhs.uk)
- Birmingham Women's Hospital NHS Foundation Trust: Gergely Toldi (Gergely.Toldi@bwnft.nhs.uk)
- Calderdale and Huddersfield NHS Foundation Trust: Karin Schwarz (Karin.Schwarz@cht.nhs.uk)
- Chesterfield Royal Hospital NHS Foundation Trust: Aiwyne Foo (aiwynefoo@nhs.net)
- Croydon University Hospital: Arun Kumar (arunkumar@nhs.net), Amy Douthwaite (amy.douthwaite@nhs.net)
- East Kent Hospitals University NHS Trust: Vimal Vasu (vimal.vasu@nhs.net), Susan Clark (susanclark7@nhs.net), Dr Magali Dubus (magali.dubus@nhs.net)
- Guy's and St Thomas' NHS Foundation Trust: Sophie Niedermaier (Sophie.Niedermaier@gstt.nhs.uk), Timothy Watts (Timothy.Watts@gstt.nhs.uk)
- Leeds Teaching Hospitals NHS Trust: Catherine Harrison (catherine.harrison10@nhs.net)
- Luton and Dunstable University Hospital NHS Foundation Trust: Sakina Ali (Sakina.Ali@ldh.nhs.uk)
- Medway NHS Foundation Trust: Helen Harizaj (helen.harizaj@nhs.net), Santosh Pattnayak (Santosh.Pattnayak@medway.nhs.uk)
- Mid Cheshire Hospitals NHS Foundation Trust: Saravanan Jayachandran (Saravanan.Jayachandran@mcht.nhs.uk), Janet Smith (janet.smith@mcht.nhs.uk)
- Norfolk and Norwich University Hospitals NHS Foundation Trust: Kenneith Yong (kenneith.yong@nhs.net)
- North Tees and Hartlepool NHS Foundation Trust: Wendy Cheadle (Wendy.Cheadle@nth.nhs.uk), wendy.cheadle@nhs.net)
- North West Anglia NHS Foundation Trust: Katharine McDevitt (Katharine.McDevitt@pbh-tr.nhs.uk), Anna Ostrzewska (Anna.Ostrzewska@pbh-tr.nhs.uk)
- Oxford University Hospitals NHS Foundation Trust: Mark Anthony (Anthony.Mark@ouh.nhs.uk), Priti Khemka (dr.pritikhemka@gmail.com)
- Portsmouth Hospitals NHS Trust: Tim J Scorrer (tim.scorrер@porthosp.nhs.uk)
- Sheffield Teaching Hospitals NHS Foundation Trust: Hazel Clargo (Hazel.Clargo@sth.nhs.uk)
- Singleton Hospital, Swansea: Dr Jean Matthes (Jean.Matthes@wales.nhs.uk)
- St George's University Hospitals NHS Foundation Trust: Nigel Kennea (Nigel.Kennea@stgeorges.nhs.uk), Hannah Davies (hannah.georgia@doctors.org.uk)
- University Hospitals of Morecambe Bay NHS Foundation Trust: Joanne Fedee (Joanne.Fedee@mbht.nhs.uk), Carol Burt (Carol.Burt@mbht.nhs.uk), Alison Hemsley (Alison.Hemsley@mbht.nhs.uk), Rebecca Kitching (Rebecca.Kitching@mbht.nhs.uk), Emma Green (Emma.Green@mbht.nhs.uk), Leigh Westwood (Leigh.Westwood@mbht.nhs.uk), Christina Jackson (Christina.Jackson@mbht.nhs.uk), Victoria Huddleston (Victoria.Huddleston@mbht.nhs.uk)

- Whittington Hospital NHS Trust: Wynne Leith (wynne.leith@nhs.net), Philippa Stilwell (philippa.stilwell@nhs.net)

Corresponding author: Shamez Ladhani, Immunisation Department, Public Health England, 61

Colindale Avenue, London NW9 5EQ, UK. Email: shamez.ladhani@phe.gov.uk

Funder: None

Word Count:

Text: 2494 words

Abstract: 244 words

1
2
3 **Abstract**
4
5

6 **Objectives:** To assess the risk of significant adverse events in premature infants receiving the novel
7 group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age
8

9 **Participants, design and setting:** In December 2015, Public Health England requested neonatal units
10 across England to voluntarily participate in a national audit; 19 units agreed to participate.
11

12 Anonymised questionnaires were completed for infants receiving 4CMenB alongside their routine
13 immunisations. For comparison, a historical cohort of premature infants receiving their primary
14 immunisations without 4CMenB or paracetamol prophylaxis was used.
15
16
17
18

19 **Main Outcome Measures:** Paracetamol use; temperature, cardiovascular, respiratory and
20 neurological status before and after vaccination; management and investigations post-vaccination,
21 including serum C-reactive protein levels, infection screens and antibiotic use.
22
23
24
25
26

27 **Results:** Complete questionnaires were returned for 133 premature infants (<35 weeks gestation)
28 who received their first dose of 4CMenB at 8 weeks of age, including 108 who received prophylactic
29 paracetamol according to national recommendations. Overall, 7% (8/108) of infants receiving
30 4CMenB with paracetamol had fever (>38°C) after vaccination compared with 20% (5/25) of those
31 receiving 4CMenB without paracetamol (p=0.06) and none of those in the historical cohort. There
32 were no significant differences between cohorts in the proportion of infants with apnoea,
33 bradycardia, desaturation and receiving respiratory support after vaccination.
34
35
36
37
38
39
40

41 **Conclusions:** 4CMenB does not increase the risk of serious adverse events in hospitalised premature
42 infants. This audit supports the current national recommendations to offer 4CMenB with other
43 routine vaccinations and prophylactic paracetamol to premature infants at their chronological age.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

In the UK, the novel, multi-component, protein-based vaccine against group B invasive meningococcus disease (4CMenB, Bexsero, GSK, Rixensart) was introduced into the national infant immunisation schedule in September 2015.[1] Infants are offered the vaccine at 2 and 4 months of age, with a booster dose at 12 months. The vaccine was quickly shown to be highly effective against meningococcal B (MenB) disease, with a nearly 50% reduction in cases among vaccine-eligible infants.[2]

Initial pre-licensure clinical trials of 4CMenB in term infants identified high rates of fever in up to 60% of cases, as well as irritability, sleepiness and poor appetite, when administered alongside routine infant immunisations.[3,4] Subsequently, a randomised controlled trial reported that prophylactic paracetamol with the first dose, administered around the time of vaccination, reduced the frequency of such adverse events to rates reported in infants receiving routine immunisations without 4CMenB.[5] Moreover, prophylactic paracetamol did not have any adverse impact on the immune response to any of the vaccine antigens. Consequently, prophylactic paracetamol at the time of vaccination with two further doses given 4-6 hours apart was recommended for all infants receiving 4CMenB along with their routine primary immunisations, including for preterm infants.[6] There has, however, been a small increase in hospitalisations for fever following vaccination, especially after the first dose.[7–10]

Premature infants are known to have a higher risk of serious bacterial infections compared to infants born at term.[11] It is therefore critical that they are protected through timely vaccination. In the UK, premature infants are recommended to receive their routine immunisations at their chronological age, without any correction for prematurity.[12] There are, however, concerns that premature infants – especially extremely premature infants and those with on-going health problems – may be at increased risk of adverse events following vaccination, particularly cardio-

1
2
3 respiratory instability and apnoea.[13] This had led some neonatal units (NNUs) to delay
4 immunisation with 4CMenB. Since cases of MenB disease increase from birth and peak by 5 months
5 of age, any delay in vaccination could leave the infant vulnerable to meningococcal disease,
6 especially because at least two priming doses of 4CMenB are required for adequate protection.[2]
7
8
9

10
11
12
13 Data on the safety and immunogenicity of 4CMenB in premature infants are limited. Following a
14 number of anecdotal reports of rapid deterioration following 4CMenB vaccination in some
15 premature infants, Public Health England (PHE) initiated a prospective national audit to assess the
16 outcomes of immunisation in premature infants receiving 4CMenB with their routine immunisations
17 in NNUs across England.[14]
18
19
20
21
22
23
24
25

26 27 **METHODS**

28 29 **Participants**

30
31 In December 2015, the Immunisation Department at PHE, through the British Association for
32 Perinatal Medicine (BAPM), invited NNUs across England to voluntarily participate in a national audit
33 to monitor the rate of adverse events in premature infants receiving 4CMenB concomitantly with
34 their routine immunisations, 19 units agreed to participate.
35
36
37
38
39
40

41 42 **Vaccination**

43
44 Participating units immunised premature infants (gestational age <37 weeks at birth) as part of
45 routine clinical care. Immunisations took place between 04/10/2015 and 25/01/2017. The
46 administered vaccines included 4CMenB, 5-in-1 DTaP-IPV-Hib (diphtheria, tetanus, pertussis,
47 inactivated polio and *Haemophilus influenzae* type b [Hib]; Infanrix-IPV-Hib®, GSK or Pediacel®,
48 Sanofi Pasteur), the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar13®; Pfizer) and the
49 oral rotavirus vaccine (Rotarix®; GSK Biologicals, Rixensart).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Clinical Management of Infants**
4

5 Any blood sampling, investigations or change in clinical management was conducted at the
6
7 discretion of the clinical team as part of clinical care. All samples were analysed at the infants' local
8
9 hospital laboratory.
10

11
12
13 **Data collection**

14
15 An anonymised questionnaire was completed by the clinical team for all infants and included
16
17 gestational age, vaccination details and paracetamol use, temperature, cardiovascular, respiratory
18
19 and neurological status prior to and for 48 hours after vaccination, changes in clinical management,
20
21 results of any blood tests or microbiological investigations performed, and use of antibiotics after
22
23 vaccination. This evaluation was conducted to audit a nationally recommended intervention and
24
25 thus met NRES criteria for a service evaluation. Formal ethics review was, therefore, not required.
26
27 All information collected was anonymised at source.
28
29
30

31
32 **Comparator Group**

33
34 For comparison, adverse reactions after vaccine administration were compared with data from a
35
36 historical cohort of premature infants who had received their primary immunisations without
37
38 4CMenB in similar NNUs across England as part of a randomised controlled trial assessing different
39
40 pneumococcal vaccination schedules (PUNS).[14] In the PUNS study, infants were vaccinated by the
41
42 study team after obtaining written informed consent from parents. Infants received 5-in-1 DTaP-
43
44 IPV-Hib (PediaceI®), meningococcal C conjugate vaccine (Menjugate®, Novartis, Siena) and PCV13.
45
46 Prophylactic paracetamol was not recommended but paracetamol could be administered post-
47
48 vaccination if required.
49
50

51
52
53 **Data Management and Analysis**
54
55
56
57
58
59
60

1
2
3 Completed questionnaires were faxed or emailed securely to PHE at regular intervals. Data were
4 entered into a custom Microsoft Access Database and transferred to Stata version 13 (Stata Corp,
5 College Station, Texas) for analysis. For comparison with the PUNS cohort, only infants born before
6 35 weeks gestation were included in the analysis. An infant was considered to have received
7 prophylactic paracetamol if the first dose was administered within two hours of vaccination. Fever
8 was defined as temperature greater than 38.0°C Data that were not normally distributed are
9 described as medians with interquartile ranges. Statistical comparisons were performed using the
10 nonparametric Kruskal-Wallis one-way analysis of variance test, X² test or Fisher's exact test as
11 appropriate. Statistical significance was defined as *P*<0.05.
12
13
14
15
16
17
18
19
20
21
22

23 RESULTS

24 Study population

25
26 Complete questionnaires were returned for 133 premature infants (<35 weeks gestation) receiving
27 their first dose of 4CMenB (4CMenB cohort). Their median gestational age at birth was 26.9 (IQR,
28 25.0-28.6) weeks and they were immunised at a median postnatal age of 63 (IQR, 59-74) days; 122
29 (92%) received concomitant vaccinations (Table 1). The PUNS cohort (n=68) had a similar gestational
30 age at birth (median 27.6 weeks, IQR 26.1-28.6) and postnatal age at vaccination (median 63 days,
31 IQR 57-68). All PUNS infants received concomitant vaccinations (Table 1). In the 48 hours prior to
32 vaccination, a similar proportion of infants in each cohort were receiving respiratory support (Table
33 1).
34

35
36 Most infants in the 4CMenB cohort received prophylactic paracetamol (n=108, 81%), with 91 infants
37 receiving all 3 paracetamol doses. None of the infants in the PUNS cohort had received prophylactic
38 paracetamol, and only five (9%) received paracetamol after vaccination for symptom management
39 (e.g. pain, unsettled). At the time of vaccination, infants receiving 4CMenB without paracetamol
40 were older (median, 75 vs. 62 days, *p*<0.001) and more likely to have episodes of desaturation (60%
41 vs. 31%, *p*<0.001) compared with infants in the PUNS cohort.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cardiorespiratory events and respiratory support after vaccination

There were no significant differences between the three cohorts in the proportion of infants with apnoea, bradycardia, desaturation and receiving respiratory support after vaccination. Infants who received 4CMenB without prophylactic paracetamol had a higher rate of desaturations before and after vaccination compared with the other two groups ($p=0.024$) (Table 2). Infants born at less than 28 weeks gestation were more likely to have an increase in desaturations (43% versus 14%, $p=0.002$) and bradycardias (35% versus 6%, $p=0.001$) compared with infants born after 28 weeks gestation. These increased rates of desaturations and bradycardias after vaccination are similar in the historical PUNS cohort.

In the prophylactic paracetamol group, 11 infants (11%) had an increase in their ventilatory support requirements, mainly infants who were spontaneously ventilating in air and required low-flow oxygen support after vaccination (Supplementary table 1); one infant in this group had Gram-negative sepsis and required intubation and ventilation. Among infants who did not receive prophylactic paracetamol, three of ten on high-flow oxygen required increased respiratory support, including one case each of continuous positive airway pressure ventilation (CPAP), biphasic positive airway pressure ventilation (BIPAP) and intubation with invasive ventilation. In the PUNS cohort, 4 infants (6%) required escalation of ventilatory support to either high flow oxygen or CPAP, and 9% self-ventilating infants had increased supplementary oxygen requirements after vaccination.

Fever after vaccination

Overall, 7% (8/108) of infants receiving 4CMenB with paracetamol had fever (38.0°C - 39.0°C) after vaccination compared with 20% (5/25) of those receiving 4CMenB without paracetamol (38.0°C - 38.7°C) ($p=0.06$) and none of those in the historical PUNS cohort ($p=0.15$ when comparing the 3 groups). In the group receiving 4CMenB without prophylactic paracetamol, 5 out of 205 (2.4%)

1
2
3 temperature measurements taken within 48 hours of vaccination were >38.0°C compared with 7 out
4 of 906 measurements (0.8%) in those who received 4CMenB with paracetamol (p=0.037).
5
6
7

8 **Sepsis assessment after vaccination**

9 Assessment for sepsis was not routinely reported for infants in the PUNS cohort. In the 4CMenB
10 cohort, 31 infants (25%) had screening bloods, 11 (9%) had a blood culture and 6 infants (5%)
11
12 received empiric IV antibiotics during the first 48 hours after vaccination. A similar proportion of
13
14 infants in the PUNS cohort (n=3, 4%) received IV antibiotics after vaccination. C-reactive protein
15
16 (CRP) results following vaccination are shown in Figure 1. Of the 17 infants in the 4CMenB cohort
17
18 who had a CRP level measured within 48 hours of vaccination, 13 (76%) had CRP levels >10 mg/dL, 4
19
20 (24%) >50 mg/dL and 1 (6%) >100 mg/dL. The median highest CRP following vaccination was 25.0
21
22 mg/dl (IQR 15.9-45.4). There was no difference in CRP levels between infants who received 4CMenB
23
24 with and without prophylactic paracetamol.
25
26
27

28 The only infant with CRP levels greater than 200mg/dL had *Enterobacter cloacae* bacteraemia, while
29
30 another infant with a peak CRP level of 73mg/dL had bacteraemia due to *Pantoea sp.*
31
32
33
34

35 **DISCUSSION**

36
37
38 4CMenB has the potential to significantly reduce the burden of invasive meningococcal disease in
39
40 infants and young children. The disease peaks at 5 months of age and, therefore, delays in
41
42 vaccination could potentially put the infants at increased risk. This is particularly the case for
43
44 premature infants who are known to be more susceptible to infection. 4CMenB is reactogenic,
45
46 especially when co-administered with the other routine infant immunisations, but clinical trials in
47
48 support the use of prophylactic paracetamol to reduce the rate of adverse events. The national
49
50 decision to offer prophylactic paracetamol to all premature infants was divisive among
51
52
53 neonatologists, with a number of units offering paracetamol only for treatment of vaccine-related
54
55
56 adverse events such as fever, either because they surmised that premature infants were less likely to
57
58
59
60

1
2
3 mount a high pro-inflammatory response to vaccination or because of safety concerns regarding
4 unnecessary paracetamol use in this vulnerable age group. We found no evidence of any increase in
5
6 significant adverse events when premature infants are administered 4CMenB with their routine
7
8 vaccinations under prophylactic paracetamol cover. Our data also indicate that most premature
9
10 infants tolerated immunisation well and remained clinically stable during the period after
11
12 vaccination.
13

14
15
16
17 Although we used a historical cohort for comparison, all the infants were vaccinated under real-life
18
19 conditions with their on-going health problems in NNUs across England. The demographics of the
20
21 PUNS and 4CMenB cohorts prior to vaccination and their outcomes after immunisation were very
22
23 similar, thus providing reassurance that the risk of adverse events has not increased following the
24
25 introduction of 4CMenB into the routine immunisation schedule. We found that post-vaccination
26
27 fever was infrequent in all groups, especially when compared with pre-licensure clinical trials in term
28
29 infants with and without prophylactic paracetamol.[4,15,16] We also found some evidence of
30
31 infants receiving 4CMenB without prophylactic paracetamol having a higher risk of fever after
32
33 vaccination. This observation would support the current national recommendation for prophylactic
34
35 paracetamol with 4CMenB for all infants.[6]
36
37
38
39
40

41 A significant concern among neonatologists was the potential for respiratory deterioration after
42
43 vaccination that might require escalation of ventilatory support. This, however, was uncommon,
44
45 with the majority of infants not requiring any additional support or only supplemental oxygen. In
46
47 particular, escalation to invasive ventilation after vaccination was uncommon in all cohorts.
48
49
50

51 There were also concerns that the use of very reactogenic vaccine may lead to a higher number of
52
53 infection screens being performed with increased consequent empiric antibiotic use. Whilst
54
55 information on investigations performed was not systematically collected for the PUNS cohort, the
56
57
58
59
60

1
2
3 proportion of infants treated for suspected (culture-negative) sepsis was low in both groups. Of
4
5 note, most infants who had a blood test during the first 48 hours after receiving 4CMenB had raised
6
7 CRP levels, which is to be expected since the vaccine, in common with all vaccinations, aims to
8
9 trigger a pro-inflammatory response to induce immune protection. [17] This [the raised CRP levels]
10
11 needs to be taken into consideration when assessing infants who appear unwell after 4CMenB
12
13 vaccination.

14
15
16
17
18 Our data confirm that a small proportion of preterm infants, especially those born under 28 weeks
19
20 gestation, will deteriorate after vaccination, irrespective of whether they receive 4CMenB with or
21
22 without paracetamol prophylaxis. It is, therefore, reassuring that the infants are being closely
23
24 monitored in neonatal units and can, therefore, receive immediate care to manage any adverse
25
26 reaction. The approach by some NNUs to delay 4CMenB vaccination until the day of hospital
27
28 discharge or to request general practitioners to give the first vaccinations to the infant in the
29
30 community is, therefore, questionable, especially given the number of infant MenB cases that might
31
32 have been prevented through timely vaccination.[2]

33 34 35 36 37 **Strengths and limitations**

38
39 This multicentre audit exemplifies the willingness of NNUs across the country to work together to
40
41 provide near-real time data to support national policy. The lack of safety data in preterm infants for
42
43 such a novel vaccine had raised concerns among neonatologists, which was fuelled by anecdotal
44
45 reports of severe adverse events, mainly relating to escalation of ventilatory support and increased
46
47 screening for sepsis because of fever and associated symptoms after vaccination. This audit began
48
49 within a few weeks of the 4CMenB programme and near real-time monitoring of the completed
50
51 questionnaires provided on-going reassurance to support the current national recommendations to
52
53 vaccinate premature infants according to their chronological age. One limitation of this analysis was
54
55 the inevitable use of a historical cohort because it would be unethical to have a contemporaneous
56
57
58
59
60

1
2
3 comparator cohort without 4CMenB. As with any historical comparison, our analysis was limited to
4 the available data. The routine vaccines offered with alongside 4CMenB, for example were similar to
5
6 but not exactly the same as those used in the clinical trial. However, the overall risk of adverse
7
8 events after immunisation is likely to be more important for clinicians, rather than risks associated
9
10 with specific vaccines or vaccine combinations. Due to the nature of audits decisions relating to
11
12 individual infants – such as fitness for vaccination, decisions to offer paracetamol prophylaxis,
13
14 managing adverse events after vaccination, initiating sepsis screening and empiric antibiotics – were
15
16 not standardised as in a clinical trial, for example, but were at the discretion of the attending
17
18 clinician. The inclusion of so many NNUs in the audit should, however, provide a representative
19
20 overview of the current status across the country.
21
22
23
24

25 **CONCLUSION**

26
27
28 When compared with previous vaccine schedules, the inclusion of 4CMenB is not associated with
29
30 any significant increase in severe adverse events among hospitalised premature infants. This audit
31
32 supports the current national recommendation to immunise premature infants at their chronological
33
34 age and to offer a routine three-dose prophylactic paracetamol course when 4CMenB is given
35
36 alongside the routine vaccinations. The Medicines and Healthcare products Regulatory Agency
37
38 (MHRA) continues to monitor the safety of all vaccines in the national immunisation programme;
39
40 any severe/unexpected adverse events should be reported to the MHRA.
41
42
43
44
45

46 **Acknowledgments:** We are grateful to Dr Alan Fenton, President of BAPM, for his kind support of
47
48 this audit.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **What is already known on this topic:**

- 4 - Premature infants are at higher risk of many vaccine preventable diseases and timely
5
6 vaccination is critical. However, there are concerns about adverse events following vaccination
7
8 of premature infants.
9 - 4CMenB (Bexsero) protects against invasive meningococcal disease but is associated with high
10
11 rates of post-vaccination fever and systemic side-effects. Paracetamol co-administration is
12
13 recommended nationally.
14 - There are currently no published data on adverse events following 4CMenB vaccination in
15
16 premature infants

17 **What this study adds:**

- 18 - Administration of 4CMenB did not increase desaturations, bradycardias and apnoeas in
19
20 hospitalised preterm infants
21
22 - We found some evidence of increased fever after vaccination in infants immunised with
23
24 4CMenB without paracetamol prophylaxis
25
26 - CRP level >10mg/dL was common after vaccination
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 REFERENCES

- 4 1 Ladhani S, Iordan, A M, Borrow R, *et al.* Enter B and W: two new meningococcal vaccine
5 programmes launched. *Arch Dis Child* 2016;**101**:91–5.
6
7 2 Parikh SR, Andrews NJ, Beebeejaun K, *et al.* Effectiveness and impact of a reduced infant
8 schedule of 4CMenB vaccine against group B meningococcal disease in England : a national
9 observational cohort study. *Lancet* 2016;**6736**:1–8. doi:10.1016/S0140-6736(16)31921-3
10
11 3 Findlow J, Borrow R, Snape MD, *et al.* Multicenter, open-label, randomized phase II
12 controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with
13 and without outer membrane vesicles, administered in infancy. *Clin Infect Dis* 2010;**51**:1127–
14 37. doi:10.1086/656741
15
16 4 Vesikari T, Esposito S, Prymula R, *et al.* Immunogenicity and safety of an investigational
17 multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered
18 concomitantly with routine infant and child vaccinations: results of two randomised trials.
19 *Lancet* 2013;**381**:825–35. doi:10.1016/S0140-6736(12)61961-8
20
21 5 Prymula R, Esposito S, Zuccotti GV, *et al.* A phase 2 randomized controlled trial of a
22 multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol
23 on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. *Hum Vaccin*
24 *Immunother* 2014;**10**.
25
26 6 Chapter 22: Meningococcal. In: *Immunisation against infectious disease*. Department of
27 Health 2016.
28
29 7 Murdoch H, Wallace L, Bishop J, *et al.* Risk of hospitalisation with fever following MenB
30 vaccination: self-controlled case series analysis. *Arch Dis Child* 2017;**102**:894–8.
31 doi:10.1136/archdischild-2017-313079
32
33 8 Nainani V, Galal U, Buttery J, *et al.* An increase in accident and emergency presentations for
34 adverse events following immunisation after introduction of the group B meningococcal
35 vaccine: An observational study. *Arch Dis Child* 2017;**102**:958–62. doi:10.1136/archdischild-
36 2017-312941
37
38 9 Ladhani SN, Riordan A. The yin and yang of fever after meningococcal B vaccination. *Arch Dis*
39 *Child* 2017;**102**:881–2. doi:10.1136/archdischild-2017-313419
40
41 10 Kapur S, Bourke T, Maney JA, *et al.* Emergency department attendance following 4-
42 component meningococcal B vaccination in infants. *Arch Dis Child* 2017;**102**:899–902.
43 doi:10.1136/archdischild-2016-311020
44
45 11 Bonhoeffer J, Siegrist C, Heath PT. Immunisation of premature infants. *Arch Dis Child*
46 2006;**91**:929–35. doi:10.1136/adc.2005.086306
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 12 Department of Health. Contraindications and special considerations (Chapter 6).
4 Immunisation against Infectious Disease: The Green Book.
5
6 2006. [https://www.gov.uk/government/collections/immunisation-against-infectious-disease-](https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book)
7 the-green-book
8
- 9 13 Sánchez PJ, Lupton AR, Fisher L, *et al.* Apnea after immunization of preterm infants. *J Pediatr*
10 1997;**130**:746–51.
11
- 12 14 Kent A, Ladhani SN, Andrews NJ, *et al.* Schedules for Pneumococcal Vaccination of Preterm
13 Infants : An RCT. *Pediatrics* 2016;**138**:e20153945.
14
- 15 15 Prymula R, Esposito S, Zuccotti GV, *et al.* A phase 2 randomized controlled trial of a
16 multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol
17 on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. *Hum Vaccin*
18 *Immunother* 2014;**10**.
19
- 20 16 Gossger N, Snape M, Yu L, *et al.* Immunogenicity and tolerability of recombinant serogroup B
21 meningococcal vaccine administered with or without routine infant vaccinations according to
22 different immunization schedules: a randomized controlled trial. *JAMA* 2012;**307**:573–82.
23
- 24 17 Pourcyrous M, Korones SB, Arheart KL, *et al.* Primary immunization of premature infants with
25 gestational age <35 weeks: cardiorespiratory complications and C-reactive protein responses
26 associated with administration of single and multiple separate vaccines simultaneously. *J*
27 *Pediatr* 2007;**151**:167–72. doi:10.1016/j.jpeds.2007.02.059
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Baseline characteristics of premature infants at the time of first vaccination in the PUNS cohort and the 4CMenB (Bexsero) cohorts with and without paracetamol.

	PUNS	Bexsero	Bexsero with paracetamol	Bexsero without paracetamol
N	68	133	108	25
Gestation	27.6 (26.1-28.6)	26.9 (25.0-28.6)	26.9 (25.2-28.5)	26.9 (23.9-28.7)
Ventilated days	NA	7 (2-29)	5.5 (1-24)	30 (7-53)*
Postnatal age	63 (57-68)	63 (59-74)	62 (59-71)	75 (64-102)*
Concomitant vaccinations	68 (100)	122 (92)	101 (94)	21 (84)
Fever	NA	3 (2)	3 (3)	0 (0)
Apnoea	3 (4)	10 (8)	9 (8)	1 (4)
Desaturations	28 (41)	48 (36)	33 (31)	15 (60)*
Bradycardia	11 (16)	19 (14)	14 (13)	5 (20)
Reduced consciousness	NA	1 (1)	1 (1)	0 (0)
Analgesia	NA	9 (7)	9 (8)	0 (0)
Respiratory Support	40 (59)	98 (74)	78 (72)	20 (80)

Median (IQR) or n(%). Respiratory support at the time of vaccination includes supplementary oxygen. Ventilated days: days of invasive ventilation only. Fever: Temperature $\geq 38^{\circ}\text{C}$. NA indicates data not available. * $p < 0.05$

Table 2: Adverse events in the 48 hours after immunisation among premature infants in the PUNS cohort and the 4CMenB (Bexsero) cohorts with and without paracetamol.

	PUNS	Bexsero (all)	Bexsero with paracetamol	Bexsero without paracetamol
N	68	122	108	25
Fever	0 (0)	13 (10)	8 (7)	5 (20)
Apnoea	11 (16)	19 (14)	18 (17)	1 (4)
Improved	3 (4)	3 (2)	2 (2)	1 (4)
Deteriorated	8 (12)	15 (11)	14 (13)	1 (4)
No change	57 (84)	102 (77)	80 (74)	22 (88)
Desaturations	26 (38)	72 (54)	53 (49)	19 (76)*
Improved	9 (13)	12 (9)	8 (7)	4 (16)
Deteriorated	18 (26)	43 (32)	33 (31)	10 (40)
No change	39 (57)	52 (39)	45 (42)	7 (28)
Bradycardia	15 (22)	44 (33)	36 (33)	8 (32)
Improved	4 (6)	5 (4)	4 (4)	1 (4)
Deteriorated	12 (18)	32 (24)	25 (23)	7 (28)
No change	50 (74)	76 (57)	60 (56)	16 (64)
Respiratory support	40 (59)	102 (77)	82 (76)	20 (80)
Improved	2 (3)	5 (4)	6 (6)	0 (0)
Deteriorated	4 (6)	14 (12)	11 (12)	3 (14)
No change	62 (91)	102 (84)	82 (82)	19 (86)
Reduced consciousness	N/A	3 (3)	3 (2)	0 (0)
Improved		0 (0)	0 (0)	0 (0)
Deteriorated		3 (2)	3 (3)	0 (0)
No change		110 (83)	88 (81)	22 (88)

Respiratory support includes supplemental oxygen. Fever was defined as temperature $\geq 38^{\circ}\text{C}$. Improved, deteriorated and no change are compared with pre-vaccination status i.e. no change means the infants either had no symptoms prior to and in the 48 hours following vaccination, or they had symptoms but these were stable before and after the vaccination period. Data on reduced consciousness were not collected for the PUNS cohort. Due to missing data, percentages may not total to 100%. Median (IQR) or n (%). NA indicates data not available. * $p < 0.05$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Distribution of CRP levels in preterm infants having a blood test after receiving 4CMenB with their routine immunisations in the neonatal unit. Dashed horizontal line marks the normal range upper limit (10mg/dL). Note the logarithmic Y axis. The two outlying results greater than 200 mg/dl dL are from an single infant with Gram negative bacteraemia.

71x51mm (300 x 300 DPI)

Supplementary data

Supplementary table 1: Change in ventilatory support in the 48 hours after vaccination in infants receiving 4CMenB with prophylactic paracetamol

		After vaccination					
Before vaccination		SVIA	Low flow O ₂	High flow O ₂	CPAP	BiPAP	IPPV
	SVIA	22	6	0	0	0	0
	Low flow O ₂	2	35	1	3	0	0
	High flow O ₂	0	2	20	0	0	1
	CPAP	0	0	0	5	0	0
	BiPAP	0	0	0	1	0	0
	IPPV	0	0	0	0	0	1

SVIA: Self-ventilating in air, CPAP: continuous positive airway pressure, BiPAP: Biphasic positive airway pressure, IPPV: Intermittent positive pressure ventilation. Respiratory support is the maximum respiratory support given immediately prior to and within 48 hours after vaccination.

Supplementary table 2: Change in ventilatory support in the 48 hours after vaccination in infants receiving 4CMenB without prophylactic paracetamol

		After vaccination					
Before vaccination		SVIA	Low flow O ₂	High flow O ₂	CPAP	BiPAP	IPPV
	SVIA	5	0	0	0	0	0
	Low flow O ₂	0	4	0	0	0	0
	High flow O ₂	0	0	7	1	1	1
	CPAP	0	0	0	2	0	0
	BiPAP	0	0	0	0	1	0
IPPV	0	0	0	0	0	0	

SVIA: Self-ventilating in air, CPAP: continuous positive airway pressure, BiPAP: Biphasic positive airway pressure, IPPV: Intermittent positive pressure ventilation. Respiratory support is the maximum respiratory support given immediately prior to and within 48 hours after vaccination.